button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population

versus interferon alpha
Ipilimumab (10 mg/kg) vs. interferon alpha 1 1.0better0.35.085 %-1.0better0.35.091 %
ipilimumab alone vs. interferon alpha 1 1.0better0.35.098 %-1.0better0.35.097 %
versus Ipilimumab (10 mg/kg)
nivolumab alone vs. Ipilimumab (10 mg/kg) 1 1.0better0.35.084 %-1.0better0.35.0100 %
versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 --1.0better0.35.0100 %
versus placebo
Ipilimumab (10 mg/kg) vs. placebo 1 1.0better0.35.0100 %-1.0better0.35.0100 %
nivolumab alone vs. placebo 1 --1.0better0.35.099 %
nivolumab plus ipilimumab vs. placebo 1 --1.0better0.35.0100 %
pembrolizumab alone vs. placebo 1 --1.0better0.35.0100 %

mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive

versus placebo
pembrolizumab alone vs. placebo 1 --1.0better0.35.0100 %

mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population

versus ipilimumab alone
nivolumab alone vs. ipilimumab alone 1 1.0better0.35.0100 %1.0better0.35.0100 %-
nivolumab plus ipilimumab vs. ipilimumab alone 2 1.0better0.35.0100 %1.0better0.35.0100 %-
versus ipilimumab followed by nivolumab
nivolumab followed by ipilimumab vs. ipilimumab followed by nivolumab 1 1.0better0.35.0100 %--
versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 1.0better0.35.0100 %1.0better0.35.0100 %-
relatlimab plus nivolumab vs. nivolumab alone 1 -1.0better0.35.0100 %-
versus Standard of Care (SoC)
tremelimumab vs. Standard of Care (SoC) 1 1.0better0.35.094 %--

mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant

versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1 1.0better0.35.073 %1.0better0.35.098 %-
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC 1 1.0better0.35.088 %1.0better0.35.099 %-

mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild

versus dacarbazine
nivolumab alone vs. dacarbazine 1 1.0better0.35.0100 %1.0better0.35.0100 %-
versus ipilimumab alone
nivolumab plus ipilimumab vs. ipilimumab alone 1 -1.0better0.35.0100 %-
versus pembrolizumab alone
atezolizumab plus cometinib vs. pembrolizumab alone 1 1.0better0.35.061 %1.0better0.35.085 %-

mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population

versus gp100
ipilimumab alone vs. gp100 1 1.0better0.35.0100 %--
ipilimumab plus gp100 vs. gp100 1 1.0better0.35.0100 %--
versus ipilimumab alone
Ipilimumab (10 mg/kg) vs. ipilimumab alone 1 1.0better0.35.098 %1.0better0.35.077 %-
ipilimumab plus gp100 vs. ipilimumab alone 1 1.0better0.35.063 %--
pembrolizumab (10mg/kg) vs. ipilimumab alone 1 1.0better0.35.0100 %1.0better0.35.0100 %-
pembrolizumab (10mg/kg) 2 weeks vs. ipilimumab alone 1 1.0better0.35.0100 %1.0better0.35.0100 %-
versus placebo plus SoC
ipilimumab plus SoC vs. placebo plus SoC 1 1.0better0.35.0100 %1.0better0.35.0100 %-
versus Standard of Care (SoC)
nivolumab alone vs. Standard of Care (SoC) 1 1.0better0.35.065 %1.0better0.35.057 %-
pembrolizumab (10mg/kg) vs. Standard of Care (SoC) 1 1.0better0.35.099 %1.0better0.35.0100 %-
pembrolizumab (2mg/kg) vs. Standard of Care (SoC) 1 1.0better0.35.088 %1.0better0.35.0100 %-

mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant

versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 1.0better0.35.081 %1.0better0.35.095 %-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons